Drug Type Small molecule drug |
Synonyms- |
Target |
Mechanism EGFR antagonists(Epidermal growth factor receptor erbB1 antagonists) |
Therapeutic Areas |
Active Indication |
Inactive Indication- |
Originator Organization |
Active Organization |
Inactive Organization- |
Drug Highest PhasePhase 1 |
First Approval Date- |
Regulation- |
Molecular FormulaC26H27F4N7O2 |
InChIKeyBFSRTTWIPACGMI-UHFFFAOYSA-N |
CAS Registry1375465-09-0 |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
EGFR Mutation Lung Cancer | Phase 1 | US | 15 Apr 2013 | |
EGFR Mutation Lung Cancer | Phase 1 | US | 15 Apr 2013 | |
EGFR Mutation Lung Cancer | Phase 1 | GB | 15 Apr 2013 |